MSD
The 2027 Future Talent Program offers a 6-month cooperative education opportunity within the Protein and Structural Chemistry department's Boston Structural Chemistry group. Participants will gain hands-on experience with modern structural biology workflows, including X-ray crystallography and cryo-EM, to determine high-resolution structures of therapeutically relevant targets. The role supports structure-based drug discovery across various research programs and provides exposure to multidisciplinary drug discovery efforts in the pharmaceutical industry.
At MSD, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for MSD.
MSD ends takeover talks with Revolution Medicines
1 month ago
Research Scientist – Protein Sciences and Structural Biology
Elanco
Scientist II, Structural Biology
Revolution Medicines
Senior Director, Head of Structural Biology
Revolution Medicines
Senior / Principal Scientist, Structural Biology
Flagship Pioneering, Inc.
Scientist - Protein Biochemist
lifelancer
Scientist - Protein Biochemist
lifelancer